@article{SCI22694,
author = {Jiasheng Wang and Yongxian Hu and He Huang},
title = {Current development of chimeric antigen receptor T-cell therapy},
journal = {Stem Cell Investigation},
volume = {5},
number = {0},
year = {2018},
keywords = {},
abstract = {Chimeric antigen receptor (CAR) T-cell therapy has achieved great success in recent years, with encouraging complete remission rate and long-term durability of response, especially in advanced B-cell malignancies. With the approval of tisagenlecleucel and axi-cel by FDA to treat refractory/relapsed acute lymphoblastic leukemia and non-Hodgkin lymphoma, our understanding of CAR T cells has been progressing rapidly. In this review, we discussed the designs of CAR T cells, factors affecting response, adverse effects, as well as application beyond B-cell malignancies.},
issn = {2313-0792}, url = {https://sci.amegroups.org/article/view/22694}
}